The Parathyroid Hormone–Related Protein (PTHrP) Gene: Use of Downstream TATA Promotor and PTHrP 1–139 Coding Pathways in Primary Breast Cancers Vary with the Occurrence of Bone Metastasis
- 1 March 1999
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 14 (3) , 406-414
- https://doi.org/10.1359/jbmr.1999.14.3.406
Abstract
We analyzed the use of different promoters and the splicing patterns of the exons encoding 5'- and 3'-untranslated sequence amounts of parathyroid hormone-related protein (PTHrP) gene products in breast cancers. Tumor samples from 74 cases of primary breast cancer that had been followed from 1 to 14 years were selected retrospectively according to the occurrence of metastasis: 18 patients developed no metastasis (NM), 56 developed metastases (M), 22 of whom developed metastases in soft tissues (MB-) and 34 of whom developed bone metastases (MB+). The amount of the 1-139 isoform mRNA was much higher in the tumors of patients who later developed metastases (M: 0.29 +/- 0.03) than in those of patients who developed no metastases (NM, 0.13 +/- 0.03; p < 0.01). This isoform mRNA was also more abundant in breast tumors from patients who developed bone metastases (MB+, 0.39 +/- 0.04) than in those of patients who developed metastases in soft tissues (MB-, 0.15 +/- 0.03; p < 0. 0001). By contrast, the amounts of the 1-141 isoform mRNA in these three groups of tumors were similar, but its concentration was higher in the tumors of premenopausal women than in those of postmenopausal women (p < 0.05). Analysis with 5' untranslated regions-specific primers showed transcription from all three putative transcription start sites of PTHrP (P1, P2, and P3). The P3-initiated transcripts were more abundant in patients who developed metastases (M, 0.31 +/- 0.03) than in the nonmetastatic tumors (NM, 0.13 +/- 0.03; p < 0.01). The amount of P3 element did not differ with the site of metastasis (BM+, 0.32 +/- 0.05; BM-, 0. 28 +/- 0.05; NS). The same trend was observed for the P2 element. However, the use of P2-initiated messages was strongly associated with the absence of estrogen receptors from the breast tumors (p < 0. 01). We thus find a close association between the pattern of PTHrP gene expression and the outcome of breast cancer. The P3-initiated start site and the presence of PTHrP 139 mRNA could help identify patients at risk of developing metastases.Keywords
This publication has 26 references indexed in Scilit:
- Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.Journal of Clinical Investigation, 1996
- Calcitonin increases transcription of parathyroid hormone-related protein via cAMPMolecular and Cellular Endocrinology, 1993
- The parathyroid hormone-related protein (PTHrP) gene preferentially utilizes a GC-rich promoter and the PTHrP 1-139 coding pathway in normal human amnionBiochemical and Biophysical Research Communications, 1992
- Localization of parathyroid hormone-related protein mrna expression in breast cancer and metastatic lesions by in situ hybridizationJournal of Bone and Mineral Research, 1992
- Parathyroid hormone related protein and skeletal morbidity in breast cancerEuropean Journal Of Cancer, 1992
- Transcription of the dystrophin gene in human muscle and non-muscle tissuesNature, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradationCell, 1986
- Chemotactic Responses of Tumor Cells to Products of Resorbing BoneScience, 1979
- The detection of skeletal metastases from mammary cancer by gamma camera scintigraphyBritish Journal of Surgery, 1969